for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Samsung Biologics Co Ltd

207940.KS

現在値

682,000.00KRW

変化

-15,000.00(-2.15%)

出来高

245,156

本日のレンジ

676,000.00

 - 

712,000.00

52週レンジ

352,000.00

 - 

863,000.00

∙ 約20分前の相場を表示しています。

適時開示

Samsung Biologics' Strategic Business Operations Continue To Support Strong Third Quarter Earnings

Oct 21 (Reuters) - Samsung Biologics Co Ltd <207940.KS>::SAMSUNG BIOLOGICS' STRATEGIC BUSINESS OPERATIONS CONTINUE TO SUPPORT STRONG THIRD QUARTER EARNINGS.Q3 REVENUE KRW 274.6 BILLION.QTRLY OPERATING PROFIT OF KRW 56.5 BILLION.

Samsung Biologics Says Co & AstraZeneca Forge Strategic Manufacturing Partnership For Global Supply

Sept 21 (Reuters) - Samsung Biologics Co Ltd <207940.KS>::SAMSUNG BIOLOGICS CO LTD - SAMSUNG BIOLOGICS (207940.KS) AND ASTRAZENECA ANNOUNCED A LONG-TERM SUPPLY AGREEMENT, VALUED AT APPROXIMATELY $330.8 MILLION .SAMSUNG BIOLOGICS AND ASTRAZENECA FORGE STRATEGIC MANUFACTURING PARTNERSHIP FOR GLOBAL SUPPLY.SAMSUNG BIOLOGICS - SAMSUNG BIOLOGICS (207940.KS) AND ASTRAZENECA ANNOUNCED A LONG-TERM SUPPLY AGREEMENT, VALUED AT APPROXIMATELY $330.8 MILLION.SAMSUNG BIOLOGICS-TO PROVIDE LARGE-SCALE COMMERCIAL MANUFACTURING FOR DRUG SUBSTANCE IN PLANT 3,DRUG PRODUCT TO SUPPORT ASTRA'S BIOLOGICS THERAPEUTICS.

Vir Biotechnology And Biogen Execute Agreement To Manufacture Sars-Cov-2 Antibodies For Potential Covid-19 Treatment

May 29 (Reuters) - Biogen Inc <BIIB.O>::VIR BIOTECHNOLOGY AND BIOGEN EXECUTE AGREEMENT TO MANUFACTURE SARS-COV-2 ANTIBODIES FOR POTENTIAL COVID-19 TREATMENT.VIR BIOTECHNOLOGY - EXECUTION OF AGREEMENT ALLOWS CO TO ADVANCE DEVELOPMENT OF ITS ANTIBODY CANDIDATES.VIR BIOTECHNOLOGY INC - EXECUTION OF AGREEMENT ALLOWS CO TO COMPLEMENT ITS EXISTING AGREEMENTS WITH WUXI BIOLOGICS AND SAMSUNG BIOLOGICS CO., LTD..

GSK Partners With Samsung Biologics To Secure Additional Manufacturing Capacity For Innovative Biopharmaceutical Portfolio

May 21 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK PARTNERS WITH SAMSUNG BIOLOGICS TO SECURE ADDITIONAL MANUFACTURING CAPACITY FOR INNOVATIVE BIOPHARMACEUTICAL PORTFOLIO.SAMSUNG BIOLOGICS WILL PROVIDE GSK WITH ADDITIONAL CAPACITY FOR LARGE-SCALE BIOPHARMACEUTICAL PRODUCT MANUFACTURING.AGREEMENT IS WORTH MORE THAN $231 MILLION US OVER NEXT EIGHT YEARS.AGREEMENT TO INITIALLY COVER COMMERCIAL PRODUCTION OF BENLYSTA (BELIMUMAB), TECH TRANSFER STARTS IN 2020, FIRST COMMERCIAL SUPPLY EXPECTED IN 2022.

Samsung Bioepis Announces Us Launch Of Ontruzant For Early And Metastatic Her2-Overexpressing Breast Cancer And Metastatic Gastric Cancer

April 15 (Reuters) - Samsung Biologics Co Ltd <207940.KS>::SAMSUNG BIOEPIS ANNOUNCES US LAUNCH OF ONTRUZANT® (TRASTUZUMAB-DTTB) FOR EARLY AND METASTATIC HER2-OVEREXPRESSING BREAST CANCER AND METASTATIC GASTRIC CANCER.SAMSUNG BIOEPIS - ONTRUZANT WILL BE INTRODUCED IN U.S. AT LIST PRICE OF ABOUT $1,325 FOR 150 MG SINGLE-DOSE VIAL & $3,709 FOR 420 MG MULTIPLE-DOSE VIAL.

Samsung Biologics Q3 Operating Profit $20 Mln, Up 125.6% Year Ago

Oct 23 (Reuters) - Samsung Biologics Co Ltd <207940.KS>::Q3 OPERATING PROFIT 23.6 BILLION WON ($20.13 million), UP 125.6% YEAR AGO.

Samsung BioLogics: S.Korea's Supreme Court Upholds Appeals Court Ruling To Set Aside Regulator's Disciplinary Actions Against Co

Sept 10 (Reuters) - Samsung BioLogics Co Ltd <207940.KS>::S.KOREA'S SUPREME COURT UPHOLDS APPEALS COURT RULING TO SET ASIDE REGULATOR'S DISCIPLINARY ACTIONS AGAINST CO.

FDA Approves Biosimilar To Humira

July 23 (Reuters) - U.S. Food and Drug Administration: :FDA APPROVES HADLIMA (ADALIMUMAB-BWWD), BIOSIMILAR TO HUMIRA (ADALIMUMAB).

Samsung BioLogics: Size Of Order Could Grow To $240 Million Or More

May 31 (Reuters) - Cytodyn Inc <CYDY.PK>::SAYS SIGNS CONTRACT MANUFACTURING DEAL WORTH $31 MILLION WITH CYTODYN.SIZE OF ORDER COULD GROW TO $240 MILLION OR MORE.

Samsung Biologics Signs Contract Manufacturing Deal Worth $33.8 Mln With An Unidentified European Drug Maker

May 17 (Reuters) - Samsung Biologics Co Ltd <207940.KS>::SAYS SIGNS CONTRACT MANUFACTURING DEAL WORTH $33.8 MILLION WITH AN UNIDENTIFIED EUROPEAN DRUG MAKER.SAYS SIZE OF ORDER COULD GROW TO $147.7 MILLION OR MORE.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up